GLP1-RA, SGLT2-I: Good first-line of defence against CVD, renal disease in diabetes
27 Aug 2020
byJairia Dela Cruz
In the treatment of patients with type 2 diabetes mellitus, both glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-dependent glucose cotransporter-2 inhibitors (SGLT2-Is) help lower blood pressure, improve glucose control without inducing weight gain, and confer cardio- and renoprotection, as shown in a study.
GLP1-RA, SGLT2-I: Good first-line of defence against CVD, renal disease in diabetes
27 Aug 2020